MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Pittsburgh’s Cohera Medical pulls in $10 million in Series C tranche

Pittsburgh’s Cohera Medical pulls in $10 million in Series C tranche

By

By Brandon Glenn

MedCity News logo

PITTSBURGH, Pennsylvania — Cohera Medical Inc., which is developing a tissue adhesive for use in tummy-tuck surgeries, received a $10 million investment commitment, the first of what it hopes will lead to a $25 million Series C round.

The $10 million commitment comes from its two major prior investors. The company plans to begin fundraising in March, with insiders getting the first shot, CEO Patrick Daly said.

The company raised a $6.8 million Series A round from private investors in 2006, followed by a $16.1 million Series B round in 2008. The Series B round was led by Pittsburgh’s Bradford Capital Partners and included participation from previous investors led by San Francisco-based Kern Whelan Capital LLC.

Asked if he was confident in Cohera’s prospects for raising the full $25 million, Daly said, “We believe what we’ve done as a company is going to make that round something that people will be interested in.”

The company’s lead product, TissuGlu, is designed to minimize fluid accumulation and other problems associated with abdominoplasty, or “tummy-tuck” surgery. In December, Cohera said it had treated with TissuGlu the first of about 40 patients in a clinical study in Germany. The company is continuing to enroll patients in the study, Daly said.

Cohera plans to seek CE Mark approval in the European Union this summer. The company hopes to begin enrolling patients in U.S. clinical trials in the fourth quarter, Daly said.

Patients who undergo tummy tucks require the insertion of drains to remove fluids that accumulate under the skin, but sometimes excess fluid still accumulates, necessitating another surgery. TissuGlu aims to strongly adhere to the skin that’s cut during surgery, reducing the amount of collected fluid and the time that drains need to be inserted, according to Cohera. Unlike some other strong “super-glue” adhesives used in tummy tucks, TissuGlu is safe for internal use, Cohera says.

Daly estimated TissuGlu’s market opportunity at between $500 million and $750 million from 2011 to 2015, according to press release.

The company is also developing an adhesive for securing soft tissues to implantable devices, such as hernia mesh, and a small-bone adhesive.The mesh product is currently in animal trials and the company expects it to be its second product to hit the market. Daly declined to provide a time frame for the mesh or bone products entering human trials.

Cohera is a portfolio company of economic development group Pittsburgh Life Sciences Greenhouse, which invested $250,000 in the company.

In case you missed it

RSS From Medical Design & Outsourcing

  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]

Leave a Reply